Dianthus Therapeutics
DNTH • NASDAQ
Dianthus Therapeutics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Marino Garcia, with a market cap of $4.3B.
CEOMarino Garcia
Next Earnings
Upcoming earnings announcement for Dianthus Therapeutics
Date
Monday, May 11, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$1.13
Revenue Estimate
$435.2K
Earnings History
Past 10 earnings reports for Dianthus Therapeutics
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 9, 2026 | Q4 2025 | -$1.43Est: -$1.01 | -41.6% | $284.0KEst: $477.0K | -40.5% |  10-K |
| Nov 5, 2025 | Q3 2025 | -$0.97Est: -$0.88 | -10.2% | $396.0KEst: $578.2K | -31.5% | 10-Q |
| Aug 7, 2025 | Q2 2025 | -$0.88Est: -$0.86 | -2.3% | $193.0KEst: $1.0M | -81.0% | 10-Q |
| May 12, 2025 | Q1 2025 | -$0.82Est: -$0.71 | -15.5% | $1.2MEst: $806.9K | +44.1% | 10-Q |
| Mar 11, 2025 | Q4 2024 | -$0.81Est: -$0.85 | +4.7% | $1.3MEst: $859.7K | +54.1% | 10-K |
| Nov 7, 2024 | Q3 2024 | -$0.74Est: -$0.61 | -21.3% | $2.2MEst: $600.0K | +262.0% | 10-Q |
| Aug 8, 2024 | Q2 2024 | -$0.51Est: -$0.55 | +7.3% | $1.9MEst: $322.8K | +477.2% | 10-Q |
| May 9, 2024 | Q1 2024 | -$0.54Est: -$0.44 | -22.7% | $874.0KEst: $460.0K | +90.0% | 10-Q |
| Mar 21, 2024 | Q4 2023 | -$0.71Est: -$1.01 | +29.7% | $457.0KEst: $310.0K | +47.4% | 10-K |
| Nov 9, 2023 | Q3 2023 | -$3.78 | — | $924.0K | — | — |